Cerylid Biosciences Ltd.

Cerylid Biosciences Ltd. is a biotechnology company based in Australia. The company focuses on discovering lead compounds for new drug development. It offers CBL1309, an anti-thrombotic compound specifically targeting pathological thrombosis under high blood flow/high shear stress conditions; CBL316, an anti-cancer compound isolated from natural sources; and natural product samples for drug discovery, including microbial cultures and plant tissue samples collected from diverse environments across Australia, Malaysia, Papua New Guinea, and Antarctica. The company also concentrates on therapies based on the inhibition of kinase targets.